首页 > 市场调查报告书 > 製药

神经疾病

市场调查报告书

商品编码

1911631

神经退化性疾病市场规模、份额和成长分析（按药物类别、疾病适应症、给药途径、最终用户和地区划分）－2026-2033年产业预测

Neurodegenerative Disease Market Size, Share, and Growth Analysis, By Drug Class, By Disease Indication, By Route of Administration, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月29日 | 出版商:

SkyQuest | 英文 178 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，全球神经退化性疾病市场规模将达到 563.9 亿美元，到 2025 年将成长至 604.5 亿美元，到 2033 年将成长至 1054.2 亿美元，在预测期（2026-2033 年）内复合成长率为 7.2%。

全球神经退化性疾病市场正经历强劲成长，这主要得益于诊断和治疗技术的进步、政府投入的增加以及患者群体结构的变化。针对阿兹海默症、帕金森氏症和肌萎缩性侧索硬化症（ALS）等疾病的创新医疗基础设施建设，凸显了全球致力于攻克这些疾病的决心。该行业的关键发展在于提高治疗效果和诊断准确性，包括将人工智慧和机器学习技术应用于脑部扫描分析和个人化治疗。此外，5G医疗平台的出现实现了远端患者监护，并加强了与神经科的沟通，从而加快了决策速度。同时，永续性措施正在推动节能型诊断工具的研发，从而提高农村地区的医疗服务可近性，并促进患者的持续管理。

全球神经退化性疾病市场驱动因素

正子断层扫描（PET）、基于生物标记的血液检测以及人工智慧驱动的神经影像等诊断技术的进步，显着提高了神经退化性疾病的早期准确识别率。这些进步有助于透过及时检测改善患者管理和治疗效果。因此，神经退化性疾病市场在诊断、治疗和监测等各个领域都经历了显着增长。这些创新不仅推动了对更有效解决方案的需求，也刺激了对临床试验和研究倡议的投资增加，从而进一步促进了全球神经退化性疾病市场的扩张。

限制全球神经退化性疾病市场的因素

全球神经退化性疾病市场面临许多限制因素，其中最主要的是先进疗法的高成本。这些疗法通常涉及昂贵的药物、持续的护理以及专业的诊断程序，其费用之高昂令人望而却步，尤其是在中低收入国家，这成为治疗的一大障碍。高额的自付费用阻碍了基因疗法和单株抗体等创新疗法的普及和广泛应用。这种限制不仅影响了这些最先进治疗的市场渗透率，也延误了早期疗育，最终影响到各个地区患者的长期治疗效果。因此，消除这些经济障碍对于改善神经退化性疾病领域关键疗法的可近性至关重要。

全球神经退化性疾病市场趋势

随着人工智慧 (AI) 融入诊断流程，全球神经退化性疾病市场正经历重大变革。这项技术进步利用 AI 演算法，透过分析患者病历、血液生物标记和脑部影像，在临床症状出现之前识别出阿兹海默症疾病，从而提高了早期检测率。因此，这项创新不仅缩短了诊断时间，也提高了临床准确性，重塑了市场动态。医疗机构对 AI 工具的日益普及是一大趋势，使 AI 成为神经诊断技术的前沿技术，并影响该领域的治疗模式。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

Biogen
Pfizer, Inc.
Hoffmann-La Roche Ltd
Merck & Co., Inc.
Novartis AG
Teva Pharmaceutical Industries Ltd.
Orion Pharma
UCB SA
ACADIA Pharmaceuticals Inc.
Lundbeck A/S

结论与建议

简介目录

Product Code: SQMIG35I2404

Global Neurodegenerative Disease Market size was valued at USD 56.39 Billion in 2024 and is poised to grow from USD 60.45 Billion in 2025 to USD 105.42 Billion by 2033, growing at a CAGR of 7.2% during the forecast period (2026-2033).

The global neurodegenerative disease market is experiencing robust growth driven by advancements in diagnostic and treatment technologies, increased government funding, and evolving patient demographics. Innovative healthcare infrastructures are being established, focusing on diseases like Alzheimer's, Parkinson's, and ALS, highlighting the global commitment to addressing these conditions. Significant developments in the industry have enhanced treatment efficacy and diagnostic accuracy, with the integration of AI and machine learning for analyzing brain scans and personalizing therapy. Additionally, the emergence of 5G-enabled medical platforms allows for real-time remote patient monitoring and improved communication with neurologists, facilitating quicker decision-making. Furthermore, the push for sustainability is spurring the creation of energy-efficient diagnostic tools, enhancing accessibility in rural areas while supporting ongoing patient management.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Neurodegenerative Disease market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Neurodegenerative Disease Market Segments Analysis

Global Neurodegenerative Disease Market is segmented by Drug Class, Disease Indication, Route of Administration, End User and region. Based on Drug Class, the market is segmented into Immunomodulator, Interferons, Decarboxylase Inhibitors, Dopamine Agonists and Others. Based on Disease Indication, the market is segmented into Multiple Sclerosis, Parkinson's Disease, Alzheimer's Disease, Spinal Muscular Atrophy (SMA) and Others. Based on Route of Administration, the market is segmented into Oral, Injection and Transdermal. Based on End User, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Neurodegenerative Disease Market

Advancements in diagnostic technologies such as PET scans, biomarker-based blood tests, and AI-driven neuroimaging have greatly enhanced the early and accurate identification of neurodegenerative diseases. This progress facilitates improved patient management and treatment outcomes through timely detection. Consequently, the market for neurodegenerative diseases is witnessing significant growth across various segments, including diagnostics, therapeutics, and monitoring. These innovations are not only driving the demand for more effective solutions but also encouraging increased investment in clinical trials and research initiatives, further propelling the expansion of the global neurodegenerative disease market.

Restraints in the Global Neurodegenerative Disease Market

The Global Neurodegenerative Disease market faces considerable constraints due to the high costs associated with advanced therapies. These treatments often involve expensive medications, continuous care, and specialized diagnostic procedures, which can be prohibitively expensive, especially in low- and middle-income countries. The substantial out-of-pocket expenses hinder the availability and adoption of innovative approaches such as gene therapy and monoclonal antibodies. This limitation not only impacts the market penetration of these cutting-edge treatments but also delays early intervention, ultimately affecting long-term patient outcomes across different regions. Addressing these financial barriers is crucial for improving access to vital therapies in the neurodegenerative disease sector.

Market Trends of the Global Neurodegenerative Disease Market

The global neurodegenerative disease market is experiencing a significant transformation driven by the integration of artificial intelligence (AI) into diagnostic processes. This technological advancement allows for enhanced early detection by leveraging AI algorithms to analyze patient histories, blood biomarkers, and brain imaging, facilitating the identification of conditions such as Alzheimer's disease before clinical symptoms manifest. Consequently, this innovation not only accelerates diagnosis times but also increases clinical accuracy, reshaping market dynamics. The growing adoption of AI tools among healthcare providers stands out as a key trend, positioning AI at the forefront of neurodiagnostic advancements and influencing treatment paradigms in the sector.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies
Customer Buying Behavior Analysis

Global Neurodegenerative Disease Market Size by Drug Class & CAGR (2026-2033)

Market Overview
Immunomodulator
Interferons
Decarboxylase Inhibitors
Dopamine Agonists
Others

Global Neurodegenerative Disease Market Size by Disease Indication & CAGR (2026-2033)

Market Overview
Multiple Sclerosis
Parkinson's Disease
Alzheimer's Disease
Spinal Muscular Atrophy (SMA)
Others

Global Neurodegenerative Disease Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Oral
Injection
Transdermal

Global Neurodegenerative Disease Market Size by End User & CAGR (2026-2033)

Market Overview
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Global Neurodegenerative Disease Market Size & CAGR (2026-2033)

North America (Drug Class, Disease Indication, Route of Administration, End User)
- US
- Canada
Europe (Drug Class, Disease Indication, Route of Administration, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drug Class, Disease Indication, Route of Administration, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drug Class, Disease Indication, Route of Administration, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Drug Class, Disease Indication, Route of Administration, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Biogen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hoffmann-La Roche Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Orion Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
UCB S.A
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ACADIA Pharmaceuticals Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lundbeck A/S
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments